|
Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
|
3 Months Ended | 12 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 28, 2013
Customer
|
Jun. 29, 2013
|
Sep. 29, 2012
Customer
|
Dec. 24, 2011
|
Sep. 28, 2013
Customer
|
Sep. 29, 2012
Customer
|
Sep. 24, 2011
|
Sep. 28, 2013
Gen-Probe Incorporated [Member]
|
Sep. 29, 2012
Gen-Probe Incorporated [Member]
|
Aug. 01, 2012
Gen-Probe Incorporated [Member]
|
Sep. 28, 2013
Molecular Diagnostics [Member]
|
Sep. 28, 2013
Other reporting units [Member]
|
Jun. 29, 2013
Technology-Based Intangible Assets [Member]
|
Sep. 28, 2013
Technology-Based Intangible Assets [Member]
Gen-Probe Incorporated [Member]
|
Sep. 29, 2012
Technology-Based Intangible Assets [Member]
Gen-Probe Incorporated [Member]
|
Sep. 28, 2013
Minimum [Member]
|
Sep. 28, 2013
Minimum [Member]
Accounts receivable [Member]
|
Sep. 29, 2012
Minimum [Member]
Accounts receivable [Member]
|
Sep. 28, 2013
Minimum [Member]
Total revenues [Member]
|
Sep. 29, 2012
Minimum [Member]
Total revenues [Member]
|
Sep. 24, 2011
Minimum [Member]
Total revenues [Member]
|
Sep. 28, 2013
Maximum [Member]
|
|
| Reclassifications [Line Items] | ||||||||||||||||||||||
| Cash equivalent maturity period | Three months or less | |||||||||||||||||||||
| Number of customers with balance greater than specified percentage | 0 | 0 | 0 | 0 | ||||||||||||||||||
| Concentration risk, percentage | 10.00% | 10.00% | 10.00% | 10.00% | 10.00% | |||||||||||||||||
| Impairment charges on tangible assets | $ 6,300,000 | $ 19,500,000 | ||||||||||||||||||||
| Impairment charges on long lived assets | 700,000 | 3,700,000 | 6,500,000 | |||||||||||||||||||
| Property plant and equipment not material charge | 0 | |||||||||||||||||||||
| Intangible assets useful life, minimum | 2 years | |||||||||||||||||||||
| Intangible assets useful life, maximum | 30 years | |||||||||||||||||||||
| Impairment charge | 1,700,000 | |||||||||||||||||||||
| Acquired In-process research and development charges | 4,500,000 | |||||||||||||||||||||
| Intangible assets from business acquisition | 1,700,000,000 | 1,570,000,000 | ||||||||||||||||||||
| In-process research and development assets | 117,000,000 | 227,000,000 | 117,000,000 | |||||||||||||||||||
| In-process research and development, value | 93,000,000 | |||||||||||||||||||||
| Total cost of completion of IPR&D projects | 49,000,000 | |||||||||||||||||||||
| Expected number of years for project completion | 4 years | |||||||||||||||||||||
| Discount rate assumption for fair value measurement of reporting unit | 10.00% | 10.00% | ||||||||||||||||||||
| Impairment of goodwill | 1,100,000,000 | 5,800,000 | 1,117,369,000 | 5,826,000 | 1,100,000,000 | |||||||||||||||||
| Percentage used to provide additional disclosure of potential goodwill impairment in the future | 10.00% | |||||||||||||||||||||
| Additional impairment charge | 195,400,000 | |||||||||||||||||||||
| Reporting unit's goodwill | 2,500,000,000 | |||||||||||||||||||||
| Damage awarded by jury | 18,800,000 | |||||||||||||||||||||
| Percentage of equity ownership at which cost-method investments would not qualify for cost-method accounting | 20.00% | |||||||||||||||||||||
| Other-than-temporary impairment charges | 6,400,000 | 0 | 2,400,000 | |||||||||||||||||||
| Sale of investment | 2,000,000 | |||||||||||||||||||||
| Defined contract term | 3 years | 5 years | ||||||||||||||||||||
| Product Warranty Term | 1 year | |||||||||||||||||||||
| Advertising cost | $ 14,100,000 | $ 29,800,000 | $ 29,000,000 | |||||||||||||||||||